Buphenyl, an FDA-approved medication for hyperammonemia, may
protect memory and prevent the progression of Alzheimer’s disease. Hyperammonemia is a life-threatening
condition that can affect patients at any age.
It is caused by abnormal, high levels of ammonia in the blood.
Studies in mice with Alzheimer’s disease (AD) have shown
that sodium phenylbutyrate, known as Buphenyl, successfully increases factors
for neuronal growth and protects learning and memory, according to neurological
researchers at the Rush University Medical Center.
Results from the National Institutes of Health funded study,
recently were published in the Journal of Biological Chemistry.